FDA approves GSK's unique myelofibrosis treatment Ojjaara
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and...
Neutral
or
Incyte News & Analysis
-
-
: Incyte shares drop after FDA approves GSK’s competing blood-cancer treatment
Incyte Corp. INCY shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK blood-cancer treatment, Ojjaara, that will...
-
Stifel maintains Incyte at 'hold' with a price target of $76.00
An analyst from Stifel maintained Incyte (NASDAQ: INCY) at 'hold' with a price target of $76.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had 10 buy...
-
Truist Securities maintains Incyte at 'buy' with a price target of $91.00
An analyst from Truist Securities maintained Incyte (NASDAQ: INCY) at 'buy' with a price target of $91.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had...
-
BMO Capital maintains Incyte at 'market perform' with a price target of $68.00
An analyst from BMO Capital maintained Incyte (NASDAQ: INCY) at 'market perform' with a price target of $68.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte...
-
RBC Capital maintains Incyte at 'sector perform' with a price target of $73.00
An analyst from RBC Capital maintained Incyte (NASDAQ: INCY) at 'sector perform' with a price target of $73.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte...
-
Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share
Incyte Corporation's (NASDAQ: INCY) Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago. Analysts had estimated $0.87. Q2 revenues increased by 25% Y/Y to $954.61 million,...
-
Incyte earnings beat by $0.28, revenue topped estimates
Investing.com - Incyte (NASDAQ: INCY) reported second quarter EPS of $0.99, $0.28 better than the analyst estimate of $0.71. Revenue for the quarter came in at $954.61M versus the consensus...
-
Incyte earnings beat by $0.28, revenue fell short of estimates
Investing.com - Incyte (NASDAQ: INCY) reported second quarter EPS of $0.99, $0.28 better than the analyst estimate of $0.71. Revenue for the quarter came in at $827M versus the consensus...
-
Incyte and Replimune Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte...
-
Citi initiates coverage of Incyte at 'buy' with a price target of $82.00
An analyst from Citi initiated coverage of Incyte (NASDAQ: INCY) at 'buy' with a price target of $82.00. Prior to this rating, Incyte had 9 buy ratings, 11 hold ratings, and 0 sell...
-
Syndax Pharmaceuticals Climbs 14% Following Positive Results form Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Syndax Pharmaceuticals (SNDX) Climbs 14% Following Positive Results form Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease Earlier: Syndax Pharmaceuticals (SNDX) and...
-
Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Syndax Pharmaceuticals (Nasdaq: NASDAQ:SNDX) and Incyte (Nasdaq: NASDAQ:INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R...
-
Incyte Phase 3 Trial Evaluating Ruxolitinib Cream in Children with Atopic Dermatitis Met Its Primary Endpoint
Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream...
-
4 big analyst cuts: PacWest downgraded, stock crashes on sale talks | Pro Recap
By Davit KirakosyanInvesting.com -- Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday.|PacWest Bancorp downgraded to Neutral, shares plunge on potential...
-
JMP Securities maintains Incyte at Market Outperform, PT $93.00
A JMP Securities analyst maintained Incyte (NASDAQ: INCY) at Market Outperform and a price target of $93.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had...
-
Morgan Stanley maintains Incyte at Equalweight, PT $74.00
A Morgan Stanley analyst maintained Incyte (NASDAQ: INCY) at Equalweight and a price target of $74.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had 10...
-
Evercore ISI maintains Incyte at In Line, PT $80.00
An Evercore ISI analyst maintained Incyte (NASDAQ: INCY) at In Line and a price target of $80.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had 9 buy...
-
Incyte earnings missed by $0.18, revenue fell short of estimates
Investing.com - Incyte (NASDAQ: INCY) reported first quarter EPS of $0.37, $0.18 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $808.67M versus the consensus...
-
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura Cream
Incyte (Nasdaq:NASDAQ:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura® (ruxolitinib) cream 1.5% to control pruritus...
-
Morgan Stanley maintains Incyte at Equalweight
A Morgan Stanley analyst maintained Incyte (NASDAQ: INCY) at Equalweight and a price target of $77.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had 9...
-
RBC Capital downgrades Incyte to Sector Perform
A RBC Capital analyst downgraded Incyte (NASDAQ: INCY) from Outperform to Sector Perform with a price target of $79.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
Incyte Announces Japanese Approval of Pemazyre
Incyte (Nasdaq: NASDAQ:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fibroblast growth factor...
-
SVB Leerink upgrades Incyte to Market Perform
A SVB Leerink analyst upgraded Incyte (NASDAQ: INCY) from Underperform to Market Perform with a price target of $61.00 from a prior price target of %currency%%price%. Prior to this rating,...
-
Incyte Issues FDA CRL for Ruxolitinib Extended-Release Tablets
Incyte (Nasdaq: NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2...
-
Incyte Announces FDA Approval of Zynyz
Incyte (Nasdaq: NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz™ (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed...
-
Incyte Reports Long-Term Extension Data from Phase 3 TRuE-V Demonstrating Long-Term Safety and Durability of Response of Opzelura
Incyte (Nasdaq: NASDAQ:INCY) today announced new 104-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura® (ruxolitinib) cream 1.5% in patients 12 years of...
-
Incyte Reports Data from Phase 2b Study of Povorcitinib
Incyte (Nasdaq: NASDAQ:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor,...
-
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib
Incyte (Nasdaq: NASDAQ:INCY) today announced that it will discontinue the Phase 3 LIMBER-304 trial following results of a pre-planned interim analysis conducted by an independent data...
-
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream for Treatment of Non-segmental Vitiligo in Adults and Adolescents
Incyte (Nasdaq:NASDAQ:INCY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the...
-
Incyte Tops Q4 EPS by 32c
Incyte (INCY) reported Q4 EPS of $0.62, $0.32 better than the analyst estimate of $0.30. Revenue for the quarter came in at $926.7 million versus the consensus estimate of $878.16...
-
Incyte earnings beat by $0.32, revenue topped estimates
Investing.com - Incyte (NASDAQ: INCY) reported fourth quarter EPS of $0.62, $0.32 better than the analyst estimate of $0.30. Revenue for the quarter came in at $926.7M versus the consensus...
-
Potential for growth has Piper Sandler starting Incyte at Overweight
By Michael Elkins Piper Sandler initiated coverage of Incyte (NASDAQ:INCY) with an Overweight rating and $100.00 price target as analysts see potential growth in the company's venture into...
-
Incyte earnings beat, Revenue misses in Q3
Investing.com - Incyte (NASDAQ:INCY) reported on Tuesday third quarter {{erl-16360||earnings that beat analysts' forecasts and revenue that fell short of expectations. Incyte announced...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
